Identification of the novel prognostic biomarker SERPINH1 reveals its relationship with immunology in gastric cancer

Abstract

Abstract Objectives One of the most prevalent deadly diseases in China and the rest of the globe is gastric cancer. Finding new and efficient biomarkers is a promising method for achieving early prevention, performing treatments, and reducing the mortality of gastric cancer; therefore, this study’s purpose is to evaluate the effectiveness of SERPINH1 as a potential biomarker. Methods Three mRNA transcriptome data sets from the GEO database were chosen for bioinformatics analysis to screen for genes connected with the formation, progression, and prognosis of GC. Then, the four genes obtained from the bioinformatics analysis were verified with the other eight data sets, including normal tissue and GC tissues samples. Finally, the connection between SERPINH1 and gastric cancer was verified using database comparisons and experiments. Results With the use of the three GEO data expression profiles, we identified 360 overlapping genes that were expressed differently. Through PPI analysis, eight GEO profile comparisons, and RT-qPCR verification of clinical tissues, SERPINH1 was deemed considerably overexpressed in gastric cancer. Analysis of each database showed that SERPINH1 was significantly associated with poor prognoses and clinical stages. An abnormal SERPINH1 expression also severely affected the expressions of some immune-related genes. EdU and Transwell assays confirmed that this finding was closely related to tumor metastasis, migration, and apoptosis. Conclusions We conclude that SERPINH1 is a promising potential prognostic marker in GC, which could provide a pathway for more in-depth research that could improve treatment efficacy and patient outcomes.